Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.

Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER.

Blood. 2015 Feb 19;125(8):e1-13. doi: 10.1182/blood-2014-10-608000. Epub 2015 Jan 8.

2.

Antigen-specific vaccines for cancer treatment.

Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L.

Hum Vaccin Immunother. 2014;10(11):3332-46. doi: 10.4161/21645515.2014.973317. Review.

3.

Antibody-based immunotherapy for malignant glioma.

Gedeon PC, Riccione KA, Fecci PE, Sampson JH.

Semin Oncol. 2014 Aug;41(4):496-510. doi: 10.1053/j.seminoncol.2014.06.004. Epub 2014 Jun 12. Review.

4.

Update on vaccine development for renal cell cancer.

Chi N, Maranchie JK, Appleman LJ, Storkus WJ.

Open Access J Urol. 2010 Aug 4;2:125-41. Review.

5.

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A.

Melanoma Res. 2013 Oct;23(5):341-8. doi: 10.1097/CMR.0b013e328364c0ed.

6.

Therapeutic cancer vaccines: past, present, and future.

Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY.

Adv Cancer Res. 2013;119:421-75. doi: 10.1016/B978-0-12-407190-2.00007-1. Review.

7.

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Mol Med. 2013 Feb 8;18:1499-508. doi: 10.2119/molmed.2012.00221.

8.

Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.

Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J.

J Immunol. 2012 Aug 15;189(4):1708-16. doi: 10.4049/jimmunol.1201271. Epub 2012 Jul 13.

9.

Targeting costimulatory molecules to improve antitumor immunity.

Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E.

J Biomed Biotechnol. 2012;2012:926321. doi: 10.1155/2012/926321. Epub 2012 Feb 12. Review.

10.

Immunotherapy for renal cell carcinoma.

Itsumi M, Tatsugami K.

Clin Dev Immunol. 2010;2010:284581. doi: 10.1155/2010/284581. Epub 2011 Jan 3.

11.

Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.

Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, Syu MH, Hsieh CY, Cheng WF.

Mol Ther. 2010 Jun;18(6):1233-43. doi: 10.1038/mt.2010.34. Epub 2010 Apr 6.

12.

Costimulatory and coinhibitory receptors in anti-tumor immunity.

Driessens G, Kline J, Gajewski TF.

Immunol Rev. 2009 May;229(1):126-44. doi: 10.1111/j.1600-065X.2009.00771.x. Review.

13.

Memory T cells need CD28 costimulation to remember.

Boesteanu AC, Katsikis PD.

Semin Immunol. 2009 Apr;21(2):69-77. doi: 10.1016/j.smim.2009.02.005. Epub 2009 Mar 5. Review.

14.

The complex role of B7 molecules in tumor immunology.

Seliger B, Marincola FM, Ferrone S, Abken H.

Trends Mol Med. 2008 Dec;14(12):550-9. doi: 10.1016/j.molmed.2008.09.010. Epub 2008 Nov 3. Review.

15.

Lung cancer immunotherapy.

Raez LE, Fein S, Podack ER.

Clin Med Res. 2005 Nov;3(4):221-8. Review.

16.

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB.

Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 7.

17.

Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC.

J Clin Invest. 2004 Jun;113(11):1515-25. Review.

18.

Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: an in vitro study.

Lu SY, Sui YF, Li ZS, Ye J, Dong HL, Qu P, Zhang XM, Wang WY, Li YS.

World J Gastroenterol. 2004 Jan;10(1):53-7.

Supplemental Content

Support Center